ISDA

Deposition Date 2021-01-07

Release Date 2021-07-14

Last Version Date 2023-10-18

Entry Detail

PDB ID:

7LAZ

Keywords:

GENE REGULATION/INHIBITOR

Title:

Crystal structure of the first bromodomain (BD1) of human BRD3 bound to ERK5-IN-1

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.30 Å

R-Value Free:

0.23

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 3
Gene (Uniprot):BRD3
Chain IDs:A, B
Chain Length:123
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:Q15059 Pfam ID:PF00439

Ligand Molecules

VYJ

Primary Citation

Differential BET Bromodomain Inhibition by Dihydropteridinone and Pyrimidodiazepinone Kinase Inhibitors.

Karim, R.M, Bikowitz, M.J, Chan, A, Zhu, J.Y, Grassie, D, Becker, A, Berndt, N, Gunawan, S, Lawrence, N.J, Schonbrunn, E.Show

J.Med.Chem. 64 15772 15786 (2021)

PMID: 34710325 DOI: 10.1021/acs.jmedchem.1c01096

Abstact

BRD4 and other members of the bromodomain and extraterminal (BET) family of proteins are promising epigenetic targets for the development of novel therapeutics. Among the reported BRD4 inhibitors are dihydropteridinones and benzopyrimidodiazepinones originally designed to target the kinases PLK1, ERK5, and LRRK2. While these kinase inhibitors were identified as BRD4 inhibitors, little is known about their binding potential and structural details of interaction with the other BET bromodomains. We comprehensively characterized a series of known and newly identified dual BRD4-kinase inhibitors against all eight individual BET bromodomains. A detailed analysis of 23 novel cocrystal structures of BET-kinase inhibitor complexes in combination with direct binding assays and cell signaling studies revealed significant differences in molecular shape complementarity and inhibitory potential. Collectively, the data offer new insights into the action of kinase inhibitors across BET bromodomains, which may aid the development of drugs to inhibit certain BET proteins and kinases differentially.

Legend

Protein

Chemical

Disease

Primary Citation of related structures